272-OR: The Efficacy of Sotagliflozin on Heart-Failure Related Outcomes Is Independent of Baseline A1C

Background: SGLT inhibitors reduce the risk of cardiovascular (CV) events in patients with heart failure (HF) and chronic kidney disease regardless of diabetes status. Although the SOLOIST-WHF and SCORED trials enrolled high CV risk patients with T2DM, participants had a wide range of baseline A1C v...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2023-06, Vol.72 (Supplement_1), p.1
Hauptverfasser:	AGGARWAL, RAHUL, BHATT, DEEPAK L., SZAREK, MICHAEL, DAVIES, MICHAEL J., BANKS, PHILLIP L., PITT, BERTRAM, STEG, PHILIPPE G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular diseases Clinical trials Congestive heart failure Diabetes mellitus Kidney diseases Regression analysis Renal failure
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!